Navigation Links
Cepheid Announces Accelerated Development of Flu A Panel Test
Date:9/9/2009

applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market. See www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the timing of new product releases, the timing and likelihood of regulatory review and approval, product performance, and future market opportunities. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen product development and manufacturing problems; uncertainties in the regulatory review process for new products; regulatory developments and practices regarding testing; customer and market acceptance of the product; the failure of the product to perform as expected, whether due to manufacturing errors, design defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the product; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2008 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    CONTACTS:
    F
'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Reports 2009 Second Quarter Results
3. Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection
4. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
5. Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
6. Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test
7. Blue Mountain Quality Resources Announces that Cepheid has Selected Blue Mountain Regulatory Asset Manager
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Announces European Release of First On-Demand Molecular Pre-Surgical Screening Test for Simultaneous Detection of Methicillin-Sensitive and Resistant S. aureus
10. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... New Jersey Plastic Surgeon and “NJ ... results. With over 30 years of experience in ... art, Dr. Rafizadeh knows what it takes to achieve ... Surgery involves the principles of proportion, harmony and balance. ... of comfort and personalized care from the moment a ...
(Date:5/28/2015)... May 28, 2015 Are policies that ... a hospital stay triggering financial pain for seniors? That’s ... Journal of Managed Care set to figure out, and ... federal rule change. , The study, “Observation Encounters and ... Vashi, MD, MPH, examined how Medicare policies that distinguish ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO ... in the role of president. , “ Bill Taaffe ... industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He will ... next phase of growth.” , Taaffe joined ICON’s U.S. ... employees to over 4,500 employees, achieving 12 consecutive years of ...
(Date:5/28/2015)... The Paw Project, an international nonprofit ... to educate the Oregon public about the harmful consequences ... Market Street and Park Avenue in Salem, Oregon's state ... Cats, Raise Your Hand,” depicts a human hand with ... graphic and anatomically-correct representation of the declaw surgery performed ...
(Date:5/28/2015)... May 28, 2015 Boston Celtics Legend ... Beth, both Genesis Foundation Board of Directors members, will ... Celebrity Fishing Tournament June 4-7. For the past 34 ... benefitting The Genesis Foundation for children by bringing together ... , The 34th John Havlicek Celebrity Fishing Tournament will ...
Breaking Medicine News(10 mins):Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 2Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 3Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2
... June 12 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... announced today that it has purchased three patents associated ... Inc. The patents relate to HIFU transducer arrays ...
... Denmark, Friday 12 June 2009: Three new studies have ... to be effective, with a good safety profile, in ... arthritis (JIA), and associated with improved Health-Related Quality of ... JIA. The data are being presented at the Paediatric ...
... directors of Abbott today declared a quarterly common dividend of 40 cents ... dividend to be paid by Abbott since 1924. The cash dividend ... of business on July 15, 2009. , , Abbott has increased ... increase earlier this year - and was again named to the ...
... summer months; 10% of all sales to be donated to ... Company (Nasdaq: TSTY ), makers of the Tastykake ... Stand Foundation (ALSF), by announcing the return of Alex,s Lemon ... leading organizations in the fight against childhood cancer, ALSF was ...
... June 2009: 92.8% of patients with systemic lupus erythematosus ... their physical and emotional quality of life (QoL), according ... at EULAR 2009, the Annual Congress of the European ... revealed that depression was the most significant factor shown ...
... FRIDAY, June 12 (HealthDay News) -- European researchers ... human,s needs. , The robots, built by ... project, were programmed to help a person put together ... process, it observes the person,s actions, such as what ...
Cached Medicine News:Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 2Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 4Health News:Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alex's Lemonade Stand Foundation 2Health News:Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alex's Lemonade Stand Foundation 3Health News:Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patients 2Health News:A Robot That Reads Your Mind? 2
(Date:5/28/2015)... 28, 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... A. Martell , to the position of Executive Chairman. ... KaloBios Board of Directors. In this new role, he ... to refine and execute on the strategic plan to ... therapeutics for orphan oncology indications with high unmet medical ...
(Date:5/28/2015)... THE WOODLANDS, Texas , May 28, 2015 /PRNewswire/ ... announced today that Lexicon management will present at the ... at 8:00 a.m. Eastern Time in New ... of Lexicon,s clinical development programs and milestones. ... Lexicon,s website at www.lexpharma.com . An archived version ...
(Date:5/28/2015)... SOUTH SAN FRANCISCO, Calif. , May 28, 2015 ... the treatment of cancer, today announced that Sean ... at the upcoming Jefferies 2015 Global Healthcare Conference ... 2:30 p.m. EDT on Tuesday, June 2, 2015. Dr. ... including the company,s Precision cancer immunotherapy and Probody drug ...
Breaking Medicine Technology:KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5Lexicon To Present At The Jefferies 2015 Healthcare Conference 2
... FRANCISCO, July 21, 2011 ClinStar, LLC , ... and Eastern Europe to the pharmaceutical and biotechnology industry, ... speak at Marcus Evans 6th Annual Clinical Research ... FL.    (Logo: http://photos.prnewswire.com/prnh/20110719/SF36975LOGO ) ...
... July 21, 2011 Endologix, Inc. (NASDAQ: ELGX ... today announced financial results for the three and six months ... and Chief Executive Officer, said, "We are pleased with our ... our growth and new product development goals for 2011.  In ...
Cached Medicine Technology:ClinStar to Present on Conducting Clinical Trials in Russia 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 3Endologix Reports 22% Second Quarter 2011 Revenue Growth 4Endologix Reports 22% Second Quarter 2011 Revenue Growth 5Endologix Reports 22% Second Quarter 2011 Revenue Growth 6Endologix Reports 22% Second Quarter 2011 Revenue Growth 7Endologix Reports 22% Second Quarter 2011 Revenue Growth 8Endologix Reports 22% Second Quarter 2011 Revenue Growth 9
Omni labs carries an extensive line of frames, lenses, soft contacts, RGP lenses, and many other products and services. It supports Zeiss, American optical, Sola, Rodenstock, Zylowear, Eyewear design...
A pre-assembled, hexagonal, revolving tower display with two round 19.75" in diameter adjustable shelves. Enjoy 3.5 square feet of elegant shelf space for your products....
... is a multi-page database similar ... a database of patient information, ... adverse reactions, etc. and can ... and invoices that are necessary ...
A pre-assembled, rectangular shadow box/wall hanging display. It have 3 adjustable shelves with tempered glass, four 50 watt halogen top lights, laminated deck, dust resistant and electrical cord wit...
Medicine Products: